查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994338

人工肺市场：2026-2032年全球市场预测（依产品类型、技术、材料类型、最终用户、应用及分销通路划分）

Artificial Lung Market by Product Type, Technology, Material Type, End User, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人工肺市场价值将达到 83.3 亿美元，到 2026 年将成长至 90.9 亿美元，到 2032 年将达到 172.4 亿美元，复合年增长率为 10.94%。

主要市场统计数据
基准年 2025 83.3亿美元
预计年份：2026年 90.9亿美元
预测年份 2032 172.4亿美元
复合年增长率 (%) 10.94%

全面概述了人工肺的发展趋势，将设备工程的进步与不断变化的临床实践和部署需求联繫起来。

在重症监护创新和先进生物材料工程的交会点，人工肺部领域正迅速发展成熟。其发展动力源自于临床上对人工呼吸器治疗方法的新需求，以及改善重症呼吸衰竭治疗效果的渴望。新型人工肺结构旨在以更高的生物相容性和便携性模拟肺部气体交换，同时治疗流程也在不断调整，以便在治疗早期阶段整合外部支持。随着关注点从急性住院治疗转向门诊和家庭支持的潜力，研发人员和医疗服务提供者必须在重症监护级别的性能、以用户为中心的设计以及长期安全性之间取得平衡。

材料技术的突破、支持系统的微型化以及护理服务模式的变革，正在重新定义人工肺的引入和整合之路。

临床团队致力于研发能够实现稳定气体交换并最大限度减少血栓形成和发炎反应的装置，而变革性的进展正在重塑人工肺技术的研发和应用。膜材料的创新正以高性能陶瓷和人工中空纤维取代传统聚合物，从而提高耐久性和血液相容性。同时，驱动主机的小型化和血流动力学管理演算法的改进，使得更灵活的部署模式成为可能，包括移动式体外循环装置和用于长期支援的潜在植入式结构。

本研究评估了 2025 年进口关税上调对供应链韧性、筹资策略和产品开发计画的结构性和营运性影响。

2025年实施的新关税制度和贸易措施为人工肺部生产和分销的整个供应链带来了巨大摩擦。关键进口零件（例如精密泵浦、特殊薄膜和生物相容性聚合物）关税的提高，增加了依赖跨境采购的组装製造商的收货成本。因此，采购团队和生产负责人正在重新审视供应商选择、避险策略和合约条款，以维持获利能力和供应的连续性。

将产品架构、膜技术、终端用户工作流程、应用场景、分销方式和材料选择与商业化策略联繫起来的实用细分见解。

了解产品、技术、终端用户、应用、分销管道和材料类型等方面的细分，对于掌握人工肺领域的整体情况价值创造至关重要。产品差异化延伸至体外膜氧合（ECMO）系统和临床试验中的植入式人工肺，其中ECMO系统进一步细分为插管、主机、氧合器和泵，这些部件共同决定了手术的复杂程度和设备面积。技术选择范围广泛，从陶瓷膜和板式膜到中空纤维膜结构，而中空纤维膜中聚醚砜和聚丙烯配方的差异决定了其在渗透性、耐久性和血液相容性方面的权衡。

为了加速人工肺技术在全球市场的普及，区域策略挑战包括协调监管差异、临床基础设施和製造地。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的监管预期、报销制度和生产物流有显着影响。在美洲，临床研究网络和重症监护基础设施为先进的体外循环疗法提供了支持，但市场准入和业务拓展需要应对不同的支付方方案和医院采购通讯协定。同时，欧洲、中东和非洲地区的监管体係错综复杂，各国既有各自的评估标准和采购规范，也努力实现协调统一，这影响实施进度和临床证据要求。

主要企业的发展趋势和竞争需求，包括优先考虑膜技术创新、製造严谨性、临床证据产生和分销管道优化，以实现可持续的差异化。

人工肺领域的竞争格局由成熟的医疗设备製造商、专业组件供应商以及致力于将转化研究成果转化为商业原型产品的临床创新者共同构成​​。主要企业正加大对膜技术、泵浦效率和整合感测器系统的投入，以在性能、易用性和生命週期成本方面脱颖而出。医疗设备原始设备製造商 (OEM) 与材料专家之间的策略合作日益普遍，双方携手开发膜结构和血液相容性涂层，从而降低血栓形成和发炎反应。

为领导者提供极具影响力的建议，以协调模组化设计、供应商多元化、临床证据计划和客製化商业模式，从而加速推广应用并增强韧性。

产业领导者应推行一项综合性议程，同时兼顾技术成熟度、供应链韧性和临床部署路径。优先采用模组化设备架构将加速替代供应商的认证，并实现产品迭代更新，而无需对平台进行彻底重新设计。对膜和涂层技术的投资应与严格的血液学测试和人体工学设计相结合，以减少不利事件并简化临床医生的工作流程。在供应链方面，组件来源多元化和探索区域性製造地可以缩短关键组装前置作业时间，同时降低关税风险和物流中断的影响。

我们透过透明、以证据为基础的调查方法来支持策略决策，该方法整合了对临床医生的访谈、材料和设备的分析、供应链映射和情境测试。

本研究途径结合了多方面的证据基础、专家定性访谈和结构化分析，旨在建构人工肺现状的全面图像。与临床医生、生物医学工程师、监管顾问和采购专家的讨论是了解临床工作流程、设备性能优先顺序和实际部署障碍的关键资讯来源。二手研究从多个角度检视了材料科学领域的技术趋势和进展，并利用了同行评审文献、监管指导文件、专利和製造商的技术规范。设备架构和供应链布局的比较检验有助于评估可製造性和物流风险。

将材料科学、设备便携性、法规遵循和供应链韧性方面的突破性进展整合起来，为临床部署和商业化提供了一条切实可行的途径。

总之，膜材料、设备小型化和系统整合方面的进步正在为人工肺技术带来转折点，影响临床实践、供应链设计和商业化策略。从仅限医院使用到门诊治疗，甚至未来可能植入式应用的转变，需要一种综合方法，将技术创新与临床工作流程、监管合规性和支付方的评估相结合。关税趋势和区域製造的考量进一步凸显了在更靠近市场的地方建立可靠的采购和生产方案的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：人工肺市场：依产品类型划分

  • 体外膜氧合装置
    • 套管
    • 主机
    • 氧合器
    • 泵浦
  • 植入式人工肺

第九章 人工肺市场：依技术划分

  • 陶瓷膜
  • 平面膜
  • 中空纤维膜
    • 聚醚砜
    • 聚丙烯

第十章：人工肺市场：依材料类型划分

  • 聚醚砜
  • 聚丙烯
  • 硅酮

第十一章 人工肺市场：依最终用户划分

  • 门诊部
  • 居家照护
  • 医院

第十二章 人工肺市场：依应用领域划分

  • 重症监护
  • 紧急运输
  • 呼吸支持

第十三章：人工肺市场：依通路划分

  • 直销
    • 向诊所销售
    • 对于医院
  • 销售代理网络
    • 医疗设备批发商
    • 药品批发商
  • 线上平台

第十四章 人工肺市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：人工肺市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 人工肺市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国人工肺市场

第十八章 中国人工肺市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abiomed, Inc.
  • ALung Technologies, Inc.
  • B. Braun Melsungen AG
  • Braile Biomedica
  • Eurosets Srl
  • Fresenius Medical Care AG & Co. KGaA
  • Getinge AB
  • Hemovent GmbH
  • Inspira Technologies OXY BHN
  • LivaNova PLC
  • MC3 Cardiopulmonary Support Inc.
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Spectrum Medical（UK）Limited
  • SynCardia Systems, LLC
  • Terumo Corporation
Product Code: MRR-1A1A064C0598

The Artificial Lung Market was valued at USD 8.33 billion in 2025 and is projected to grow to USD 9.09 billion in 2026, with a CAGR of 10.94%, reaching USD 17.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.33 billion
Estimated Year [2026] USD 9.09 billion
Forecast Year [2032] USD 17.24 billion
CAGR (%) 10.94%

An integrative introduction to the evolving artificial lung landscape that connects advances in device engineering with shifting clinical practices and adoption imperatives

The artificial lung arena is rapidly maturing at the intersection of critical care innovation and advanced biomaterials engineering, driven by renewed clinical demand for alternatives to mechanical ventilation and improved outcomes in severe respiratory failure. Emerging device architectures aim to replicate pulmonary gas exchange with greater biocompatibility and portability, while procedural ecosystems adapt to integrate extracorporeal support earlier in the care pathway. As attention shifts from acute, in-hospital use toward ambulatory and home-support potential, developers and providers must reconcile intensive-care-grade performance with user-centric design and long-term safety profiles.

Concurrent advances in membrane technologies, pump miniaturization, and sensor-driven control systems are enabling more efficient extracorporeal platforms and nascent implantable solutions that could redefine chronic respiratory support. Regulatory frameworks and clinical evidence requirements are evolving to address these hybrid technologies, increasing the emphasis on real-world performance and human factors. Investors, supply chain partners, and clinical stakeholders are therefore tasked with navigating a highly technical landscape where translational research, manufacturability, and post-market surveillance are equally determinative of commercial success.

In this context, organizations should prioritize cross-disciplinary collaboration spanning materials science, critical care medicine, and regulatory strategy. By aligning technological roadmaps with clinical workflows and reimbursement realities, stakeholders can better bridge proof-of-concept milestones and sustainable adoption pathways for next-generation artificial lung systems.

How materials breakthroughs, miniaturization of support systems, and shifting care delivery models are jointly redefining pathways for artificial lung adoption and integration

Transformative shifts are reshaping the development and deployment of artificial lung technologies as clinical teams demand devices that deliver consistent gas exchange while minimizing thrombogenicity and inflammatory activation. Membrane material innovations are replacing legacy polymers with higher-performance ceramics and engineered hollow fibers, enhancing durability and hemocompatibility. At the same time, the miniaturization of drive consoles and the refinement of hemodynamic management algorithms are enabling more flexible deployment models, including mobile extracorporeal units and potential implantable constructs that are designed for longer-term support.

The clinical landscape is also changing in terms of care setting and stakeholder expectations. There is growing interest in extending extracorporeal support beyond intensive care units to pre-hospital emergency transport and ambulatory settings, which requires ruggedized devices, simplified interfaces, and telemonitoring capabilities. Concurrently, payer and procurement stakeholders are scrutinizing total cost of care and comparative effectiveness, pushing manufacturers to demonstrate not only technical superiority but also operational viability and clear pathways to reimbursement. These intersecting forces are producing a market environment where technological differentiation, clinical integration, and value demonstration are decisive for adoption trajectories.

Assessing the structural and operational consequences of escalated import duties in 2025 on supply chain resilience, sourcing strategies, and product development timelines

The imposition of new tariff regimes and trade measures in 2025 has introduced measurable friction across the supply chains that support artificial lung manufacturing and distribution. Increased duties on key imported components such as precision pumps, specialty membranes, and biocompatible polymers have elevated landed costs for assemblers that rely on cross-border sourcing. As a result, procurement teams and manufacturing planners are reassessing supplier concentration, hedging strategies, and contractual terms to preserve margin and continuity of supply.

Tariff-driven cost pressures have a cascading effect on product development timelines and commercial models. Engineering teams are under pressure to qualify alternative materials and suppliers more rapidly, while quality assurance functions must accelerate validation activities to maintain regulatory compliance. At the distribution level, channel partners are renegotiating pricing structures and service agreements to reflect higher input costs. Moreover, increased import duties are incentivizing nearshoring and regional manufacturing footprints, prompting capital allocation decisions to favor production sites closer to end markets to mitigate tariff exposure.

These dynamics also affect long-term strategic planning, as organizations balance the immediate need to absorb or pass through incremental costs with the broader objective of securing resilient supply chains. Stakeholders that proactively diversify supplier networks, invest in local manufacturing capability, and optimize product design for modularity are better positioned to manage tariff volatility while preserving access to critical components and technologies.

Actionable segmentation insights that connect product architecture, membrane technologies, end-user workflows, application scenarios, distribution approaches, and material selections to commercialization strategies

Understanding segmentation across product, technology, end user, application, distribution channel, and material type is essential for mapping value creation in the artificial lung domain. Product differentiation spans extracorporeal membrane oxygenation systems and investigational implantable artificial lungs, with extracorporeal systems further decomposed into cannula, consoles, oxygenators, and pumps that together determine procedural complexity and footprint. Technology choices range from ceramic and flat sheet membranes to hollow fiber configurations, and within hollow fibers, distinctions between polyethersulfone and polypropylene formulations inform trade-offs in permeability, durability, and hemocompatibility.

End users encompass ambulatory care centers, home care programs, and hospitals, each presenting distinct clinical workflows, staffing models, and procurement cycles that influence product requirements and support expectations. Applications vary across critical care, emergency transport, and respiratory support, and these use cases place different demands on device portability, setup time, and monitoring capabilities. Distribution channels include direct sales, distributor networks, and online platforms; direct sales models often target clinic and hospital accounts with integrated service offerings, while distributor relationships may leverage medical device and pharmaceutical distribution expertise to broaden market presence. Material selection, including polyethersulfone, polypropylene, and silicone, intersects with technology choice and device architecture to shape biocompatibility, sterilization pathways, and component longevity.

Taken together, these segmentation layers create a matrix of requirements that manufacturers must navigate. Product teams should align design specifications to the dominant combinations of technology, material, and end-user needs in their target geographies, while commercial teams should tailor channel strategies and service propositions to match the operational realities of hospitals, ambulatory centers, and home-based care providers.

Regional strategic imperatives that reconcile regulatory variation, clinical infrastructure, and manufacturing footprints to accelerate adoption of artificial lung technologies across global markets

Regional dynamics exert a powerful influence on regulatory expectations, reimbursement practices, and manufacturing logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical research networks and critical care infrastructure support advanced extracorporeal therapies, but market entry and scaling require navigation of diverse payer systems and hospital procurement protocols. Meanwhile, Europe, Middle East & Africa present a complex regulatory mosaic where harmonization efforts coexist with country-specific assessment criteria and procurement norms that shape deployment timelines and clinical evidence requirements.

Asia-Pacific markets demonstrate a spectrum of readiness, from high-volume, innovation-forward centers to regions prioritizing cost-effective and scalable solutions. Manufacturing capacity and supplier ecosystems in Asia-Pacific can offer competitive advantages for component sourcing, yet quality system alignment with international regulatory standards remains a critical gating factor. Across all regions, logistics, tariffs, and local clinical practice patterns inform decisions about regional production hubs, inventory positioning, and support infrastructure. Successful regional strategies integrate regulatory intelligence, localized clinical partnerships, and adaptive pricing models to align product value propositions with payer expectations and care delivery realities.

Organizations planning global rollouts should adopt a region-sensitive approach that sequences regulatory submissions, clinical engagements, and supply chain investments to reflect local priorities and operational constraints. This calibrated strategy reduces commercialization friction and accelerates meaningful clinical adoption across heterogeneous markets.

Key company patterns and competitive imperatives that prioritize membrane innovation, manufacturing rigor, clinical evidence generation, and channel orchestration for durable differentiation

Competitive dynamics in the artificial lung space are shaped by a mix of established medical device manufacturers, specialized component suppliers, and clinical innovators translating translational research into commercial prototypes. Key players invest in membrane science, pump efficiency, and integrated sensor systems to differentiate on performance, ease of use, and lifecycle costs. Strategic partnerships between device OEMs and materials specialists are increasingly common, enabling co-development of membrane structures and hemo-compatible coatings that reduce clot formation and inflammatory responses.

Beyond product innovation, companies that excel in commercialization are the ones that build robust clinical evidence generation programs and engage early with health technology assessment bodies. Manufacturing excellence and quality systems are equally critical; suppliers that can demonstrate scalable, reproducible production of membrane modules and precision pumps secure durable competitive advantages. Channel strategy also matters-organizations that combine direct clinical engagement with selective distributor relationships and digital platforms can extend reach while maintaining control over key customer interactions. Finally, leadership teams that prioritize post-market surveillance and iterative design improvements create a virtuous cycle of safety enhancements and clinician trust, which is especially important for devices that interface directly with blood and respiratory physiology.

High-impact recommendations for leaders to align modular engineering, supplier diversification, clinical evidence programs, and tailored commercial models to drive adoption and resilience

Industry leaders should pursue an integrated agenda that simultaneously addresses technological refinement, supply chain resilience, and clinical adoption pathways. Prioritizing modular device architectures will accelerate qualification of alternative suppliers and support iterative product updates without wholesale platform redesign. Investments in membrane and coating technologies should be coupled with rigorous hemocompatibility testing and human factors engineering to reduce adverse events and simplify clinician workflows. On the supply chain front, diversifying component sources and exploring regional manufacturing nodes can mitigate tariff exposure and logistical disruption while shortening lead times for critical assemblies.

Commercially, organizations should align go-to-market models to end-user needs by tailoring service bundles for hospitals, ambulatory centers, and home care settings, and by building training and remote-monitoring capabilities that lower barriers to adoption. Regulatory strategy must be proactive, embedding post-market data strategies and health economic modeling into submissions to demonstrate clinical utility and value to payers. Finally, leadership should institutionalize scenario-based planning to stress-test product roadmaps against policy shifts, supply interruptions, and payer behavior changes. These parallel actions will strengthen an organization's ability to convert engineering innovation into reliable, widely adopted clinical solutions.

A transparent, evidence-driven methodology integrating clinician interviews, materials and device analyses, supply chain mapping, and scenario testing to inform strategic decision-making

The research approach combines a multi-source evidence base, qualitative expert interviews, and structured analysis to create a comprehensive view of the artificial lung landscape. Primary inputs include discussions with clinicians, biomedical engineers, regulatory advisers, and procurement specialists to capture clinical workflows, device performance priorities, and real-world adoption barriers. Secondary research encompasses peer-reviewed literature, regulatory guidance documents, patents, and manufacturer technical specifications to triangulate technological trends and materials science advances. Comparative analysis of device architectures and supply chain footprints supports assessments of manufacturability and logistical risk.

Analytical methods include technology mapping to compare membrane types and pump platforms, value-chain decomposition to highlight cost and quality drivers, and scenario analysis to anticipate operational responses to policy shifts and tariff changes. Quality control measures include cross-validation of claims with multiple independent sources and critical appraisal of evidence quality for clinical outcomes. The methodology emphasizes transparency in assumptions and traceability of data sources while refraining from projecting numerical market estimates. This layered approach ensures the findings are grounded in empirical evidence and stakeholder perspectives, supporting actionable insights for developers, payers, and providers.

A conclusive synthesis that ties material science breakthroughs, device portability, regulatory alignment, and supply chain resilience into pragmatic pathways for clinical adoption and commercialization

In conclusion, advances in membrane materials, device miniaturization, and systems integration are converging to create an inflection point in artificial lung technologies, with implications for clinical practice, supply chain design, and commercialization strategies. The movement from exclusively in-hospital use toward ambulatory and potentially implantable applications requires a holistic approach that aligns engineering innovation with clinician workflows, regulatory compliance, and payer value assessment. Tariff dynamics and regional manufacturing considerations further underscore the need for resilient sourcing and near-market production options.

Stakeholders that adopt a segmented, regionally aware strategy-one that synchronizes product design, channel approach, and evidence generation-will be better positioned to navigate the complex path from prototype to clinical standard of care. Ultimately, the organizations most likely to succeed will be those that combine technical excellence in membrane and pump systems with disciplined commercialization practices, robust quality systems, and an adaptive supply chain capable of responding to policy and market shocks. This integrated posture will accelerate the translation of technological promise into tangible clinical benefits for patients with severe respiratory insufficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Lung Market, by Product Type

  • 8.1. Extracorporeal Membrane Oxygenation System
    • 8.1.1. Cannula
    • 8.1.2. Console
    • 8.1.3. Oxygenator
    • 8.1.4. Pump
  • 8.2. Implantable Artificial Lung

9. Artificial Lung Market, by Technology

  • 9.1. Ceramic Membrane
  • 9.2. Flat Sheet Membrane
  • 9.3. Hollow Fiber Membrane
    • 9.3.1. Polyethersulfone
    • 9.3.2. Polypropylene

10. Artificial Lung Market, by Material Type

  • 10.1. Polyethersulfone
  • 10.2. Polypropylene
  • 10.3. Silicone

11. Artificial Lung Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Care
  • 11.3. Hospitals

12. Artificial Lung Market, by Application

  • 12.1. Critical Care
  • 12.2. Emergency Transport
  • 12.3. Respiratory Support

13. Artificial Lung Market, by Distribution Channel

  • 13.1. Direct Sales
    • 13.1.1. Clinic Accounts
    • 13.1.2. Hospital Accounts
  • 13.2. Distributor Network
    • 13.2.1. Medical Device Distributors
    • 13.2.2. Pharmaceutical Distributors
  • 13.3. Online Platforms

14. Artificial Lung Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Artificial Lung Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Artificial Lung Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Artificial Lung Market

18. China Artificial Lung Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abiomed, Inc.
  • 19.6. ALung Technologies, Inc.
  • 19.7. B. Braun Melsungen AG
  • 19.8. Braile Biomedica
  • 19.9. Eurosets Srl
  • 19.10. Fresenius Medical Care AG & Co. KGaA
  • 19.11. Getinge AB
  • 19.12. Hemovent GmbH
  • 19.13. Inspira Technologies OXY B.H.N.
  • 19.14. LivaNova PLC
  • 19.15. MC3 Cardiopulmonary Support Inc.
  • 19.16. Medtronic PLC
  • 19.17. MicroPort Scientific Corporation
  • 19.18. Nipro Corporation
  • 19.19. Spectrum Medical (UK) Limited
  • 19.20. SynCardia Systems, LLC
  • 19.21. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL LUNG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL LUNG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GCC ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)